Boehringer Ingelheim and Eli Lilly have launched their new diabetes combination therapy Glyxambi across the US, offering patients a new option for blood glucose control.

Glyxambi - a combination of Jardiance (empagliflozin) with Trajenta (linagliptin) - is the first treatment in the US to marry the dual mechanisms of action of a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor in a once-daily pill.

SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney, while DPP-4 inhibitors increase hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose.

The US Food and Drug Administration issued a green light for Glyxambi last month as an adjunct to diet and exercise to boost glycaemic control in adults with type II diabetes when both empagliflozin and linagliptin are appropriate treatments.